Two months is barely enough time for most startups to finalize incorporation paperwork. Gestala, a Chengdu-based brain-computer interface company, used that window to close what appears to be the largest angel round in China's neurotechnology sector: CN¥150 million, roughly $21.6 million.
The March 11-12 announcement raised eyebrows not just for the sum — unusually large for a seed-stage company anywhere — but for the investor lineup. Guosheng Capital and Daotong Investment co-led the round, joined by Qingsong Capital, Gobi Partners, and a mix of strategic players including rehabilitation robotics maker Fourier Intelligence and recruiting platform Liepin. TechCrunch reported that overall investor commitments topped US$58 million, with founder Peng Lei suggesting the raise valued Gestala somewhere between $100 million and $200 million. Not bad for a company that went public on January 1.
Perhaps what's drawing interest is the technology itself. While most brain-computer interface ventures — in China and elsewhere — are chasing variations on implantable electrodes, Gestala is betting on focused ultrasound. It's a non-invasive play, one that sidesteps the surgical risks and regulatory hurdles that come with drilling into skulls.
The company's platform pairs low-intensity focused ultrasound for neuromodulation with functional ultrasound imaging to monitor brain activity. Peng has described a staged development roadmap: start with basic modulation, build toward closed-loop systems, eventually reach sonogenetics. Whether that timeline proves realistic is another matter entirely.
For now, the immediate application is chronic pain management. Gestala has set up research collaborations with three heavyweight Chinese hospitals: Huashan Hospital at Fudan University, West China Hospital at Sichuan University, and Peking Union Medical College Hospital. The company is aiming for a Class III filing with China's National Medical Products Administration by the end of 2026 — an ambitious target for a pain neuromodulation device that, as of mid-March, existed largely in prototype form.
The funding is earmarked for the usual early-stage priorities: R&D, initial clinical work, and headcount expansion. Gestala plans to grow from around 15 employees to approximately 35 by year's end, according to company statements. Manufacturing infrastructure is also on the agenda, with Peng highlighting China's cost advantages in clinical trials and its established supply chains for medical devices.
Gestala's formal registration in Chengdu came on September 5, 2024, backed by Shanda Group founder Tianqiao Chen and the Tianqiao & Chrissy Chen Institute, a philanthropic venture focused on brain research. The company maintains dual presences in Chengdu's Tianfu International Bio City and Shanghai's Minhang District — a setup that splits the difference between government incentives and proximity to capital.
Timing may be half the story here. Beijing has been making coordinated moves into neurotechnology, treating brain-computer interfaces as a strategic priority rather than a niche research curiosity. In August 2025, seven ministries including the Ministry of Industry and Information Technology issued what they called "Implementation Opinions," sketching out targets for industry breakthroughs by 2027 and global competitiveness by 2030. By December, a national brain science fund worth 11.6 billion yuan was unveiled at a BCI expo in Shenzhen.
Gestala's angel round, while record-setting at the seed stage, sits within a broader funding landscape. StairMed, another Chinese BCI company, pulled in CN¥350 million in a Series B this past February. BCIFlex raised over CN¥300 million in Series A funding around mid-2025. The money is flowing, in other words — though whether it translates into viable commercial products remains an open question.
For now, Gestala's prototype and regulatory milestones are company-stated targets, not independently verified achievements. The technology is promising, the backers are credible, and the policy environment is supportive. What happens between now and that 2026 NMPA filing will determine whether this angel round was prescient or premature.
